Single-Cell Biotherapeutics Market: Trends, Growth Drivers and Regional Insights (2025–2034)

This report provides an in-depth analysis of the global single-cell biotherapeutics market, highlighting key trends, growth drivers, and regional insights. It is published by Towards Healthcare, a sister firm of Precedence Research, specializing in comprehensive healthcare market intelligence.

Ottawa, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The global single-cell biotherapeutics market is experiencing robust growth and is expected to reach hundreds of millions in revenue between 2025 and 2034. This expansion is driven by shifting consumer preferences and rapid technological advancements transforming the industry.

The market’s growth is fueled by innovations in proteomics, transcriptomics, and genomics, alongside rising investment in research and development. North America currently leads the market, supported by a strong healthcare infrastructure, substantial funding, and the presence of major biotech players. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, propelled by government initiatives and a rapidly expanding biotechnology sector.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5751

Key Takeaways

North America dominated the market in 2024.
Asia Pacific is expected to witness the fastest growth in the single-cell biotherapeutics market from 2025 to 2035.
By product, the consumables & reagents segment dominated the market in 2024.
By product, the software & data analysis tools segment is expected to witness the fastest growth from 2025 to 2035.
By therapeutic application, the oncology segment led the market in 2024.
By therapeutic application, the neurology segment is expected to witness the fastest growth from 2025 to 2035.
By technology, the single-cell RNA sequencing (scRNA-seq) segment dominated the market in 2024.
By technology, the CRISPR screening at the single-cell level segment is expected to witness the fastest growth from 2025 to 2035.
By disease indication, the cancer segment led the market in 2024.
By disease indication, the rare genetic disorders segment is expected to witness the fastest growth from 2025 to 2035.
By end user, the pharmaceutical & biotechnology companies segment led the market in 2024.
By end user, the academic & research institutes segment is expected to witness the fastest growth from 2025 to 2035.

What is Single-Cell Biotherapeutics?

The single-cell biotherapeutics market is driven by growing demand for personalized medicines and technological innovations in single-cell analysis. The single-cell biotherapeutics refer to the advanced therapies that are analyzed, developed, and optimized with the use of single-cell technologies. They are being used in the development of various therapies, their optimization, drug development, early disease diagnosis, as well as for various other R&D applications.

What are the Major Growth Drivers Single-Cell Biotherapeutics Market?

Growth in R&D is the major driver, increasing the use of single-cell biotherapeutics. They are being used to develop advanced treatment options, drug discovery and development, and novel diagnostic platforms. Additionally, the growing advancements in single-cell technologies, the growing demand for cell and gene therapies, and the increasing rare diseases are other market drivers.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Key Drifts in the Single-Cell Biotherapeutics Market?

The market has been expanding due to the growing collaborations and funding to launch and enhance the use of various single-cell biotherapeutics platforms.

In April 2025, a collaboration between Hamilton Bonaduz AG and Singleron Biotechnologies was announced, where they combined the world-class automation expertise of Hamilton and the pioneering single-cell technology of Singleron to develop an instrument that fully automates the complete single-cell sequencing workflow for around 32 samples, from cell suspension, that is Tensor.
In April 2025, to develop and launch next-generation single-cell multi-omic solutions, a collaboration between 1Cell.Ai and BiSkryb Genomics was announced. Therefore, the accuracy of the characterization and detection of rare mutations in single cells will be enhanced, promoting the earlier detection and targeted therapy development in this collaboration.
In February 2025, a $25 million Series A funding round was announced by Atrandi Biosciences, which is a life sciences company pioneering next-generation single-cell analysis technology. This funding will be used to enhance the product development, promote scientific discoveries, support the growth of semi-permeable capsule (SPC) technology, and the company’s expansion across the U.S. market.

What is the Significant Challenge in the Single-Cell Biotherapeutics Market?

Data interpretation complexity is the major limitation in the market. This increases the demand for technologies, tools, and experts for their accurate interpretation to reduce the chances of misinterpretations. Moreover, high cost, technical limitations, and limited infrastructure are other market challenges.

Regional Analysis

Why did North America Dominate the Single-Cell Biotherapeutics Market in 2024?

In 2024, North America captured the biggest revenue share of the market due to the presence of robust industries, which contributed to the increased R&D, enhancing the use of single-cell biotherapeutics platforms. Moreover, the growth in the development of single-cell therapies and technological innovations has also enhanced their use. Additionally, the investments and funding also enhanced their use, which contributed to the market growth.

Download the single region market report @ https://www.towardshealthcare.com/download-sample/5751

What Made the Asia Pacific Show the Fastest Growth in the Single-Cell Biotherapeutics Market in 2024?

Asia Pacific is expected to host the fastest growth in the market during the forecast period, due to the expanding healthcare sector, which is increasing the adoption of single-cell biotherapeutic platforms. Additionally, the growing diseases, startups, and investments are also supporting their utilization and use for various applications. Thus, all these factors, along with the growing demand for personalized therapies, are promoting the market growth.

Segmental Insights

By product analysis

Why Did the Consumables & Reagents Segment Dominate in the Single-Cell Biotherapeutics Market in 2024?

By product, the consumables & reagents segment led the market in 2024, driven by their repetitive use. They were essential for various purposes, which increased their demand. At the same time, growth in personalized therapies and bioproduction also contributed to their increased use.

By product, the software & data analysis tools segment is expected to show the highest growth from 2025 to 2035. Their use is increasing for the interpretation of the vast amount of complex data generated during the process. Moreover, they also help in providing deeper insights and optimization of therapies.

By therapeutic application analysis

Which Therapeutic Application Type Segment Held the Dominating Share of the Single-Cell Biotherapeutics Market in 2024?

By therapeutic application, the oncology segment held the dominating share of the market in 2024, due to the single-cell biotherapeutics increased application in the detection of diverse tumor cells. Moreover, they also helped in the precise detection of cancer biomarkers. This increased their use in the development of various cancer treatment options.

By therapeutic application, the neurology segment is expected to show the highest growth from 2025 to 2035. The use of single-cell biotherapeutics in the detection of neurodegenerative disease mechanisms is increasing. Additionally, they are supporting the development of various CNS therapies.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

By technology analysis

What Made Single-Cell RNA Sequencing (scRNA-seq) the Dominant Segment in the Single-Cell Biotherapeutics Market in 2024?

By technology, the single-cell RNA sequencing (scRNA-seq) segment led the market in 2024, driven by its increased transcriptomics applications. Moreover, it can detect cellular heterogeneity, which has increased its use in cancer and rare diseases. They are also being used to detect targets and develop personalized medicines.

By technology, the CRISPR screening at the single-cell level segment is expected to show the highest growth rate from 2025 to 2035. They are being used in the detection of specific disease targets, which is accelerating the drug development process. This is increasing their use in the research involving oncology, immunology, and other areas.

By disease indication analysis

Why Did the Cancer Segment Dominate in the Single-Cell Biotherapeutics Market in 2024?

By disease indication, the cancer segment held the largest share of the market in 2024, as the single-cell biotherapeutics helped in detecting diverse cancer cell types. It helped in discovering its mechanisms, targets, and biomarkers. They also enhanced the development of various cancer therapies.

By disease indication, the rare genetic disorders segment is expected to show the highest growth rate from 2025 to 2035. The single-cell biotherapeutics help in providing deeper cellular insights and enhancing the accurate detection of defective genes. This is increasing their use in the development of targeted and personalized treatment options.

By end-user analysis

How the Pharmaceutical & Biotechnology Companies Segment Dominated the Single-Cell Biotherapeutics Market in 2024?

By end user, the pharmaceutical & biotechnology companies segment held the largest share of the market in 2024, due to growth in the drug discovery and development. Additionally, the growth in personalized medicines, cell and gene therapies has also increased the use of single-cell biotherapeutics. Moreover, the rise in R&D investment also supported these developments.

By end user, the academic & research institutes segment is expected to show the highest growth rate from 2025 to 2035. Growing R&D focused on immunology, cancer, and neurology is encouraging the use of single-cell biotherapeutics in these institutes. Moreover, the adoption is supported by growing government funding and industrial collaborations.

Browse More Insights of Towards Healthcare:

The global single-use consumables market was valued at USD 2.99 billion in 2024 and is projected to reach USD 3.49 billion by 2025. By 2034, the market is expected to surpass USD 13.83 billion, expanding at a robust CAGR of 16.56%.

The single-use duodenoscope market, starting at USD 160.5 million in 2024, is estimated to grow to USD 206.14 million in 2025 and reach approximately USD 1,977.84 million by 2034, reflecting a strong CAGR of 28.44% between 2025 and 2034.

The single-cell sequencing market is set to grow from USD 1.63 billion in 2024 to USD 1.88 billion in 2025, eventually surpassing USD 6.65 billion by 2034, at a CAGR of 15.05%.

The single-use assemblies market, valued at USD 13.25 billion in 2024, is expected to rise to USD 15.39 billion in 2025 and reach around USD 58.44 billion by 2034, growing at a CAGR of 16.15% over the forecast period.

The single-use downstream bioprocessing market is projected to increase from USD 1.57 billion in 2024 to USD 1.79 billion in 2025, ultimately reaching USD 5.9 billion by 2034, at a CAGR of 14.24%.

The single-use sensors market is estimated at USD 0.47 billion in 2024, expected to grow to USD 0.54 billion in 2025, and projected to reach USD 1.86 billion by 2034, expanding at a CAGR of 15.04%.

The single nucleotide polymorphism (SNP) genotyping market, starting at USD 6.48 billion in 2024, is projected to grow to USD 7.24 billion in 2025 and reach approximately USD 19.48 billion by 2034, at a CAGR of 11.7%.

The single-cell omics market is forecast to grow from USD 1.94 billion in 2024 to USD 2.35 billion in 2025 and reach USD 12.05 billion by 2034, reflecting a CAGR of 16.14%.

The single-use bioreactors market, valued at USD 4.59 billion in 2024, is expected to grow to USD 5.38 billion in 2025 and reach USD 22.46 billion by 2034, expanding at a CAGR of 17.21%.

The single-use pump market, evaluated at USD 451.81 million in 2023, is projected to attain USD 2,133.2 million by 2034, growing at a CAGR of 15.95% from 2024 to 2034.

The global single-use bioprocessing market is expected to increase from USD 30.77 billion in 2025 to USD 112.2 billion by 2034, registering a CAGR of 15.46% throughout the forecast period.

Recent Developments in the Single-Cell Biotherapeutics Market

In February 2025, a series of roadmap innovations was introduced by Illumina, Inc., enhancing its sequencing applications and omics solutions, including CRISPR technologies, genomics, epigenetics, spatial transcriptomics, data analytics software, and single-cell analysis.
In February 2025, the first single-cell RNA sequencing kits supporting a profile of 5 million cells and 384 samples in a single run, that is, Evercode™ WT Penta and Penta 384, were launched by Parse Biosciences.

Single-Cell Biotherapeutics Market Key Players List

Bio-Rad Laboratories
10x Genomics
Illumina
BD
Mission Bio, Inc.
Qiagen
RareCyte, Inc.
Thermo Fisher Scientific
CYTENA GmbH
TAKARA BIO INC.
BGI
Ancilia Biosciences
Merck KGaA
Acuitas Therapeutics
Oxford Nanopore Technologies
PacBio
Novogene Co
Roche

Download the Competitive Landscape market report @ https://www.towardshealthcare.com/download-sample/5751

Segments Covered in The Report

By Product Type

Instruments
Consumables & Reagents
Software & Data Analysis Tools
Services

By Therapeutic Application

Oncology
Neurology
Immunology
Infectious Diseases
Cardiovascular Diseases
Metabolic Disorders
Genetic Disorders
Others

By Technology

Single-Cell RNA Sequencing (scRNA-seq)
Flow Cytometry
Mass Cytometry (CyTOF)
qPCR
Microfluidics
High-Content Imaging
CRISPR Screening at Single-Cell Level

By Disease Indication

Cancer
Autoimmune Diseases
Neurodegenerative Diseases
Infectious Diseases
Rare Genetic Disorders

By End Use

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Hospitals & Clinical Laboratories
Contract Research Organizations (CROs)

By Region

North America

U.S.
Canada

Asia Pacific

China
Japan
India
South Korea
Thailand

Europe

Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway

Latin America

Brazil Mexico
Argentina

Middle East and Africa (MEA)

South Africa
UAE
Saudi Arabia
Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5751

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.